Comparison of efficacy and safety of salvage-line nivolumab monotherapy between 240 and 480 mg for advanced esophageal squamous cell carcinoma.

被引：0
|
作者：
Murashima, Yuko
Yamamoto, Shun
Hirose, Toshiharu
Kadono, Toru
Ikeda, Go
Ohara, Akihiro
Itoyama, Mai
Yokoyama, Kazuki
Honma, Yoshitaka
Ishiyama, Koshiro
Oguma, Junya
Daiko, Hiroyuki
Kato, Ken
机构：
[1] Natl Canc Ctr, Dept Head & Neck, Esophageal Med Oncol, Tokyo, Japan
[2] Natl Canc Ctr, Dept Esophageal Surg, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
317
引用
下载
收藏
页码：317 / 317
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Immune Checkpoint Inhibitor in Advanced Esophageal Squamous Cell Carcinoma: A Meta-Analysis
    Gu, Yi-Min
    Shang, Qi-Xin
    Zhuo, Yue
    Zhou, Jian-Feng
    Liu, Bo-Wei
    Wang, Wen-Ping
    Che, Guo-Wei
    Chen, Long-Qi
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [32] Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma
    Jian Zhao
    Junmei Lei
    Junyan Yu
    Chengyan Zhang
    Xuefeng Song
    Ninggang Zhang
    Yusheng Wang
    Suxiang Zhang
    Investigational New Drugs, 2020, 38 : 500 - 506
  • [33] Short-term safety of adjuvant nivolumab therapy after neoadjuvant docetaxel plus cisplatin and 5-FU therapy for locally advanced esophageal squamous cell carcinoma.
    Hirose, Toshiharu
    Yamamoto, Shun
    Kadono, Toru
    Ikeda, Go
    Ohara, Akihiro
    Itoyama, Mai
    Yokoyama, Kazuki
    Honma, Yoshitaka
    Ishiyama, Koshiro
    Oguma, Junya
    Daiko, Hiroyuki
    Kato, Ken
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 312 - 312
  • [34] Impact of PD-L1 combined positive score (CPS) on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma.
    Matsubara, Yuki
    Toriyama, Kazuhiro
    Kadowaki, Shigenori
    Ogata, Takatsugu
    Nakazawa, Taiko
    Kato, Kyoko
    Nozawa, Kazuki
    Narita, Yukiya
    Honda, Kazunori
    Masuishi, Toshiki
    Bando, Hideaki
    Ando, Masashi
    Tajika, Masahiro
    Hosoda, Waki
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study
    Liu, Ying
    Ge, Qingqing
    Xu, Shuning
    Li, Ke
    Liu, Ying
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [36] Comparison of efficacy and safety of neoadjuvant regimens for resectable esophageal squamous cell carcinoma: A meta-analysis
    Wang, Ting
    Cai, Liyu
    Guo, Zefeng
    You, Peimeng
    Liu, Shengbo
    Qiu, Hongrui
    Li, Hao
    Wu, Shaowei
    Zhou, Haiyu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] Safety and efficacy of tislelizumab plus chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma
    Qiu, Hai-Bo
    THORACIC CANCER, 2020, 11 (12) : 3419 - 3421
  • [38] Efficacy and Safety of Apatinib with or Without Radiation Therapy as Second-Line or Beyond Therapy in Patients with Advanced/Recurrent Esophageal Squamous Cell Carcinoma
    Li, T.
    Lv, J.
    Wang, Q.
    Fan, Y.
    Wang, J.
    Song, Y.
    Liang, L.
    Wu, L.
    Lang, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E33 - E34
  • [39] The efficacy and toxicities of combined lobaplatin with paclitaxel as a first-line chemotherapy for advanced esophageal squamous cell carcinoma
    Chen, Ming-Qiu
    Chen, Cheng
    Lu, Hai-Jie
    Xu, Ben-Hua
    JOURNAL OF THORACIC DISEASE, 2015, 7 (10) : 1749 - 1755
  • [40] Efficacy and safety of pembrolizumab combined with albumin-bound paclitaxel and nedaplatin for advanced esophageal squamous cell carcinoma
    Yan, Fang
    Chen, Longpei
    Ying, Mingzhen
    Li, Jie
    Fu, Qiang
    IMMUNOTHERAPY, 2024, 16 (05) : 305 - 317
12345